Skip to main content
DongKookPharmaceuticalCo.,Ltd. logo

DongKookPharmaceuticalCo.,Ltd. — Investor Relations & Filings

Ticker · 086450 ISIN · KR7086450004 KO Manufacturing
Open in API
Filings indexed 160 across all filing types
Latest filing 2020-09-09 Director's Dealing
Country KR South Korea
Listing KO 086450

About DongKookPharmaceuticalCo.,Ltd.

https://www.dkpharm.co.kr/en/

DongKook Pharmaceutical Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and distribution of medical products. Established in 1968, the company focuses on improving human health and quality of life. Its product portfolio includes prescription and non-prescription drugs, with key therapeutic areas in anesthetics, contrast media, anti-cancer agents, antibiotics, and oral healthcare treatments. The company operates its own Active Pharmaceutical Ingredient (API) synthesis facilities and invests in research and development to create innovative therapeutic solutions. It provides both finished products and raw materials to domestic and international markets.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure document in South Korea (DART system) where company insiders report their shareholdings and changes therein. This falls under the category of Director's Dealing (DIRS), as it details the share ownership and changes (specifically a stock split) for an executive (Lee Kyu-jin) of Dongkook Pharmaceutical.
2020-09-09 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (DART). This type of filing is specifically used for reporting insider shareholdings and changes in ownership by company directors or major shareholders, which corresponds to the 'Director's Dealing' category.
2020-09-09 Korean
주권매매거래정지해제(액면분할 주권 변경상장)
Delisting Announcement Classification · 100% confidence The document is a short regulatory notice from the Korea Exchange regarding the lifting of a trading suspension for Dongkook Pharmaceutical due to a stock split. It does not fit into specific categories like financial reports, dividends, or director dealings. As it is a regulatory announcement regarding market operations, it falls under the RNS category.
2020-09-09 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard South Korean regulatory disclosure (DART filing) required when directors or major shareholders change their holdings in a company. While it involves share ownership, it is specifically a report on the status of holdings by insiders/major shareholders rather than a 'Director's Dealing' (which usually refers to individual trades) or 'Major Shareholding Notification' (which refers to the 5% rule). Given the specific regulatory nature of this filing in the Korean market, it falls under the 'Regulatory Filings' category as the most accurate classification for this type of insider ownership report.
2020-09-09 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes due to stock splits, and special relationships of major shareholders. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2020-08-31 Korean
주권매매거래정지(주식의 병합, 분할 등 전자등록 변경, 말소)
Delisting Announcement Classification · 100% confidence The document is a short regulatory notice regarding the suspension of stock trading for Dongkook Pharmaceutical due to a stock split. It cites specific exchange regulations (KOSDAQ market rules) and provides the effective date and reason for the suspension. Since it is a regulatory announcement regarding trading status and does not fit into specific categories like M&A or dividend announcements, it falls under the general regulatory filing category.
2020-08-19 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.